558 related articles for article (PubMed ID: 26713604)
1. Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors.
Wang J; Ding Q; Fujimori H; Motegi A; Miki Y; Masutani M
Oncotarget; 2016 Feb; 7(7):7701-14. PubMed ID: 26713604
[TBL] [Abstract][Full Text] [Related]
2. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
Cruz C; Castroviejo-Bermejo M; Gutiérrez-Enríquez S; Llop-Guevara A; Ibrahim YH; Gris-Oliver A; Bonache S; Morancho B; Bruna A; Rueda OM; Lai Z; Polanska UM; Jones GN; Kristel P; de Bustos L; Guzman M; Rodríguez O; Grueso J; Montalban G; Caratú G; Mancuso F; Fasani R; Jiménez J; Howat WJ; Dougherty B; Vivancos A; Nuciforo P; Serres-Créixams X; Rubio IT; Oaknin A; Cadogan E; Barrett JC; Caldas C; Baselga J; Saura C; Cortés J; Arribas J; Jonkers J; Díez O; O'Connor MJ; Balmaña J; Serra V
Ann Oncol; 2018 May; 29(5):1203-1210. PubMed ID: 29635390
[TBL] [Abstract][Full Text] [Related]
3. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
[TBL] [Abstract][Full Text] [Related]
4. Phosphoglycerate mutase 1 regulates dNTP pool and promotes homologous recombination repair in cancer cells.
Qu J; Sun W; Zhong J; Lv H; Zhu M; Xu J; Jin N; Xie Z; Tan M; Lin SH; Geng M; Ding J; Huang M
J Cell Biol; 2017 Feb; 216(2):409-424. PubMed ID: 28122957
[TBL] [Abstract][Full Text] [Related]
5. Triapine disrupts CtIP-mediated homologous recombination repair and sensitizes ovarian cancer cells to PARP and topoisomerase inhibitors.
Lin ZP; Ratner ES; Whicker ME; Lee Y; Sartorelli AC
Mol Cancer Res; 2014 Mar; 12(3):381-393. PubMed ID: 24413181
[TBL] [Abstract][Full Text] [Related]
6. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
7. Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.
Dev H; Chiang TW; Lescale C; de Krijger I; Martin AG; Pilger D; Coates J; Sczaniecka-Clift M; Wei W; Ostermaier M; Herzog M; Lam J; Shea A; Demir M; Wu Q; Yang F; Fu B; Lai Z; Balmus G; Belotserkovskaya R; Serra V; O'Connor MJ; Bruna A; Beli P; Pellegrini L; Caldas C; Deriano L; Jacobs JJL; Galanty Y; Jackson SP
Nat Cell Biol; 2018 Aug; 20(8):954-965. PubMed ID: 30022119
[TBL] [Abstract][Full Text] [Related]
8. Loss of NFBD1/MDC1 disrupts homologous recombination repair and sensitizes nasopharyngeal carcinoma cells to PARP inhibitors.
Wang Z; Zuo W; Zeng Q; Qian Y; Li Y; Liu C; Wang J; Zhong S; Bu Y; Hu G
J Biomed Sci; 2019 Feb; 26(1):14. PubMed ID: 30717758
[TBL] [Abstract][Full Text] [Related]
9. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
[TBL] [Abstract][Full Text] [Related]
10. H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours.
Dibitetto D; Liptay M; Vivalda F; Dogan H; Gogola E; González Fernández M; Duarte A; Schmid JA; Decollogny M; Francica P; Przetocka S; Durant ST; Forment JV; Klebic I; Siffert M; de Bruijn R; Kousholt AN; Marti NA; Dettwiler M; Sørensen CS; Tille JC; Undurraga M; Labidi-Galy I; Lopes M; Sartori AA; Jonkers J; Rottenberg S
Nat Commun; 2024 May; 15(1):4430. PubMed ID: 38789420
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
12. Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment.
Ip LR; Poulogiannis G; Viciano FC; Sasaki J; Kofuji S; Spanswick VJ; Hochhauser D; Hartley JA; Sasaki T; Gewinner CA
Oncotarget; 2015 Apr; 6(12):10548-62. PubMed ID: 25868852
[TBL] [Abstract][Full Text] [Related]
13. 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
Hong R; Ma F; Zhang W; Yu X; Li Q; Luo Y; Zhu C; Jiang W; Xu B
BMC Cancer; 2016 Sep; 16(1):725. PubMed ID: 27613518
[TBL] [Abstract][Full Text] [Related]
14. Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
García-Parra J; Dalmases A; Morancho B; Arpí O; Menendez S; Sabbaghi M; Zazo S; Chamizo C; Madoz J; Eroles P; Servitja S; Tusquets I; Yelamos J; Lluch A; Arribas J; Rojo F; Rovira A; Albanell J
Eur J Cancer; 2014 Oct; 50(15):2725-34. PubMed ID: 25128455
[TBL] [Abstract][Full Text] [Related]
15. Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.
Lin ZP; Zhu YL; Lo YC; Moscarelli J; Xiong A; Korayem Y; Huang PH; Giri S; LoRusso P; Ratner ES
PLoS One; 2018; 13(11):e0207399. PubMed ID: 30444904
[TBL] [Abstract][Full Text] [Related]
16. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
17. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.
Arun B; Akar U; Gutierrez-Barrera AM; Hortobagyi GN; Ozpolat B
Int J Oncol; 2015 Jul; 47(1):262-8. PubMed ID: 25975349
[TBL] [Abstract][Full Text] [Related]
18. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
[TBL] [Abstract][Full Text] [Related]
19. Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors.
Amin O; Beauchamp MC; Nader PA; Laskov I; Iqbal S; Philip CA; Yasmeen A; Gotlieb WH
BMC Cancer; 2015 Oct; 15():817. PubMed ID: 26510816
[TBL] [Abstract][Full Text] [Related]
20. BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
Mio C; Gerratana L; Bolis M; Caponnetto F; Zanello A; Barbina M; Di Loreto C; Garattini E; Damante G; Puglisi F
Int J Cancer; 2019 Feb; 144(4):755-766. PubMed ID: 30259975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
